Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:DGXNASDAQ:EXASNASDAQ:FTRENASDAQ:NTRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDGXQuest Diagnostics$178.19+0.6%$175.49$135.47▼$182.38$19.89B0.49991,539 shs263,066 shsEXASExact Sciences$54.12+4.5%$52.59$39.97▼$72.83$10.17B0.982.56 million shs3.72 million shsFTREFortrea$5.17-0.7%$5.22$3.97▼$28.41$467.43M1.591.88 million shs279,871 shsNTRANatera$168.62+0.3%$158.53$92.14▼$183.00$23.02B1.741.41 million shs482,656 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDGXQuest Diagnostics-0.90%-1.42%+1.95%+5.87%+27.77%EXASExact Sciences-0.21%-1.01%-8.40%+18.67%+17.32%FTREFortrea+0.39%-4.59%+25.30%-35.24%-77.07%NTRANatera+2.44%-1.64%+7.01%+16.83%+50.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDGXQuest Diagnostics4.9271 of 5 stars2.34.04.24.73.42.52.5EXASExact Sciences4.6977 of 5 stars4.53.00.04.72.12.50.6FTREFortrea3.9406 of 5 stars3.91.00.00.02.90.83.8NTRANatera1.304 of 5 stars1.52.00.00.03.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDGXQuest Diagnostics 2.69Moderate Buy$185.734.24% UpsideEXASExact Sciences 2.95Moderate Buy$70.4030.07% UpsideFTREFortrea 1.86Reduce$15.00190.42% UpsideNTRANatera 3.00Buy$184.639.50% UpsideCurrent Analyst Ratings BreakdownLatest NTRA, EXAS, FTRE, and DGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025EXASExact SciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $65.005/22/2025FTREFortreaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/15/2025NTRANateraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$205.00 ➝ $210.005/14/2025FTREFortreaCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/14/2025FTREFortreaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $8.005/14/2025FTREFortreaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$7.00 ➝ $5.005/13/2025FTREFortreaBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$6.00 ➝ $5.005/9/2025NTRANateraUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$211.00 ➝ $218.005/9/2025NTRANateraBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$160.00 ➝ $190.005/6/2025DGXQuest DiagnosticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$180.00 ➝ $190.005/2/2025EXASExact SciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$55.00 ➝ $75.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDGXQuest Diagnostics$9.87B2.02$13.47 per share13.23$61.38 per share2.90EXASExact Sciences$2.76B3.70$5.87 per share9.22$12.98 per share4.17FTREFortrea$2.70B0.17$1.57 per share3.30$15.19 per share0.34NTRANatera$1.70B13.57N/AN/A$9.05 per share18.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDGXQuest Diagnostics$871M$7.9122.5216.992.498.81%15.11%6.65%7/22/2025 (Estimated)EXASExact Sciences-$1.03B-$5.51N/A108.2539.42-36.06%-3.75%-1.68%7/30/2025 (Estimated)FTREFortrea-$328.50M-$8.79N/A4.040.35-29.43%2.84%1.06%8/11/2025 (Estimated)NTRANatera-$190.43M-$1.47N/AN/AN/A-10.36%-18.29%-11.68%8/14/2025 (Estimated)Latest NTRA, EXAS, FTRE, and DGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/22/2025Q2 2025DGXQuest Diagnostics$2.56N/AN/AN/A$2.73 billionN/A5/12/2025Q1 2025FTREFortrea-$0.07$0.02+$0.09-$6.25$609.63 million$651.30 million5/8/2025Q1 2025NTRANatera-$0.59-$0.50+$0.09-$0.50$446.68 million$501.83 million5/1/2025Q1 2025EXASExact Sciences-$0.37-$0.21+$0.16-$0.54$688.58 million$706.79 million4/22/2025Q1 2025DGXQuest Diagnostics$2.15$2.21+$0.06$1.94$2.63 billion$2.65 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDGXQuest Diagnostics$3.201.80%N/A40.46%14 YearsEXASExact SciencesN/AN/AN/AN/AN/AFTREFortreaN/AN/AN/AN/AN/ANTRANateraN/AN/AN/AN/AN/ALatest NTRA, EXAS, FTRE, and DGX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/14/2025DGXQuest Diagnosticsquarterly$0.801.86%7/7/20257/7/20257/21/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDGXQuest Diagnostics0.841.441.31EXASExact Sciences0.972.732.38FTREFortrea1.220.970.97NTRANateraN/A3.873.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDGXQuest Diagnostics88.06%EXASExact Sciences88.82%FTREFortreaN/ANTRANatera99.90%Insider OwnershipCompanyInsider OwnershipDGXQuest Diagnostics8.16%EXASExact Sciences1.20%FTREFortrea0.38%NTRANatera7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDGXQuest Diagnostics56,000111.64 million102.53 millionOptionableEXASExact Sciences7,000188.64 million186.37 millionOptionableFTREFortrea15,50090.50 million90.16 millionOptionableNTRANatera4,434136.55 million126.17 millionOptionableNTRA, EXAS, FTRE, and DGX HeadlinesRecent News About These CompaniesArtemis Investment Management LLP Boosts Stake in Natera, Inc. (NASDAQ:NTRA)5 hours ago | marketbeat.comOppenheimer Asset Management Inc. Trims Stake in Natera, Inc. (NASDAQ:NTRA)June 27 at 4:03 AM | marketbeat.comHere's How Much $100 Invested In Natera 10 Years Ago Would Be Worth TodayJune 26 at 10:06 PM | benzinga.comStanley Druckenmiller's Updated Portfolio: 7 Top Stocks in 2025June 26 at 7:04 AM | money.usnews.com1 Volatile Stock to Own for Decades and 2 to Brush OffJune 26 at 7:04 AM | msn.comEnvestnet Portfolio Solutions Inc. Sells 2,578 Shares of Natera, Inc. (NASDAQ:NTRA)June 25 at 3:32 AM | marketbeat.comNatera, Inc. (NASDAQ:NTRA) Receives $184.63 Consensus Price Target from AnalystsJune 25 at 2:03 AM | americanbankingnews.comChevy Chase Trust Holdings LLC Acquires 16,678 Shares of Natera, Inc. (NASDAQ:NTRA)June 24 at 6:38 AM | marketbeat.comNarwhal Capital Management Has $1.41 Million Stake in Natera, Inc. (NASDAQ:NTRA)June 24 at 5:13 AM | marketbeat.comQ1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology StocksJune 23, 2025 | msn.com2,042 Shares in Natera, Inc. (NASDAQ:NTRA) Acquired by Whalen Wealth Management Inc.June 23, 2025 | marketbeat.comTrueMark Investments LLC Buys New Shares in Natera, Inc. (NASDAQ:NTRA)June 23, 2025 | marketbeat.comNatera, Inc. (NASDAQ:NTRA) Receives Average Rating of "Buy" from AnalystsJune 22, 2025 | marketbeat.com1,864 Shares in Natera, Inc. (NASDAQ:NTRA) Purchased by Institute for Wealth Management LLC.June 21, 2025 | marketbeat.com3 Reasons We Love Natera (NTRA)June 20, 2025 | msn.comNatera, Inc. (NASDAQ:NTRA) Shares Sold by Fifth Third BancorpJune 20, 2025 | marketbeat.comGuided Capital Wealth Management LLC Has $1.85 Million Stock Holdings in Natera, Inc. (NASDAQ:NTRA)June 19, 2025 | marketbeat.comPrecision Wealth Strategies LLC Makes New $803,000 Investment in Natera, Inc. (NASDAQ:NTRA)June 16, 2025 | marketbeat.comElevation Point Wealth Partners LLC Sells 1,616 Shares of Natera, Inc. (NASDAQ:NTRA)June 16, 2025 | marketbeat.comHere's How Much You Would Have Made Owning Natera Stock In The Last 10 YearsJune 13, 2025 | benzinga.comHarbor Capital Advisors Inc. Sells 4,030 Shares of Natera, Inc. (NASDAQ:NTRA)June 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBigBear.ai: Risky AI Stock or Defense Tech Opportunity?By Jeffrey Neal Johnson | May 28, 2025View BigBear.ai: Risky AI Stock or Defense Tech Opportunity?3 Blockchain Stocks to Profit in a Decentralized WorldBy Chris Markoch | June 24, 2025View 3 Blockchain Stocks to Profit in a Decentralized WorldUber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesBy Leo Miller | June 25, 2025View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesScience Applications International Is a Wicked Hot Buy in JuneBy Thomas Hughes | June 9, 2025View Science Applications International Is a Wicked Hot Buy in JuneForget the Fed: Home Depot Is the Real Gauge of the U.S. ConsumerBy Jeffrey Neal Johnson | June 19, 2025View Forget the Fed: Home Depot Is the Real Gauge of the U.S. ConsumerNTRA, EXAS, FTRE, and DGX Company DescriptionsQuest Diagnostics NYSE:DGX$178.18 +1.13 (+0.64%) As of 11:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.Exact Sciences NASDAQ:EXAS$54.12 +2.31 (+4.47%) As of 11:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Fortrea NASDAQ:FTRE$5.16 -0.04 (-0.67%) As of 11:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.Natera NASDAQ:NTRA$168.62 +0.45 (+0.26%) As of 11:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Skyworks Stock Down 16% in 2025, Poised for AI Edge Surge Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Tesla: The Next Month Could Make or Break the Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
